

**ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDER
TO AID PUBLIC COMMENT**

In the Matter of Endo International plc

File No. 151-0137

Docket No. C-4539

The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Endo International plc (“Endo”) that is designed to remedy the anticompetitive effects resulting from Endo’s acquisition of Par Pharmaceutical Holdings, Inc. (“Par”). Under the terms of the proposed Consent Agreement, Endo is required to divest all of its rights and assets related to generic glycopyrrolate tablets and generic methimazole tablets.

The proposed Consent Agreement has been placed on the public record for thirty days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again evaluate the proposed Consent Agreement, along with the comments received, to make a final decision as to whether it should withdraw from the proposed Consent Agreement or make final the Decision and Order (“Order”).

Pursuant to an Agreement and Plan of Merger executed on May 18, 2015, Endo proposes to acquire Par for approximately \$8 billion. The Commission alleges in its Complaint that the

Pharmaceuticals, Inc.—currently supply generic methimazole in the United States. The combined company would supply approximately 67% of the generic methimazole tablet market.

II. Entry

